INGN Stock Analysis: Buy, Sell, or Hold?
INGN - Inogen Inc
$6.51
0.08 (1.24%)
▲
5d:
+0.77%
30d:
+1.56%
90d:
+0.93%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When INGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INGN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: INGN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: INGN is currently trading at $6.51, which is considered slightly high relative to its 30-day fair value range of $6.21 to $6.53. From a valuation perspective, the stock is trading at a discount (Forward PE: -24.7) compared to its historical average (120.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, INGN is in a uptrend. Immediate support is located at $5.88, while resistance sits at $6.72.
Market Sentiment: INGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.67 (+97.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INGN is in a uptrend. Immediate support is located at $5.88, while resistance sits at $6.72.
Market Sentiment: INGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.67 (+97.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$6.21 -
$6.53
Company Quality Score
58/100
(HOLD)
Options IV Signal
6th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
84.6%
All Signals
- BULLISH: Options cheap (IV 6th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 97.0% below Wall St target ($12.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$6.21 -
$6.53
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.51
(7.8%)
Support & Resistance Levels
Support Level
$5.88
Resistance Level
$6.72
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-24.73
Wall Street Target
$12.67
(+97.0%)
Revenue Growth (YoY)
3.4%
Earnings Growth (YoY)
87.3%
Profit Margin
-7.1%
PE vs Historical
-24.7 vs 120.2
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 2:27 PM ET
Data refreshes hourly during market hours. Next update: 3:27 PM
Data refreshes hourly during market hours. Next update: 3:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 60 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 61 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 59 HOLD |
